Streptokinase and Enoxaparin as an Alternative to Fibrin-Specific Lytic-Based Regimens
Abstract Background: Enoxaparin was superior to unfractionated heparin (UFH), regardless of fibrinolytic agent in ST-elevation myocardial infarction (STEMI) patients receiving fibrinolytic therapy in ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction 25) trial. Objective: This post hoc analysis compared outcomes with streptokinase plus enoxaparin to the standard regimen of fibrin-specific lytic (FSL) plus UFH and to the newer combination of FSL plus enoxaparin. Methods: In ExTRACT-TIMI 25, STEMI patients received either streptokinase or a FSL (alteplase, reteplase or tenecteplase) at the physician’s discretion and were randomized to enoxaparin or UFH, stratified by fibrinolytic type. Thirty-day outcomes were adjusted for baseline characteristics, region, in-hospital percutaneous coronary intervention (PCI) and a propensity score for the choice of lytic. Results: The primary trial endpoint of 30-day death/myocardial infarction (MI) occurred in fewer patients in the streptokinase-enoxaparin cohort (n = 2083) compared with FSL-UFH (n = 8141) [10.2% vs 12.0%, adjusted odds ratio [$ OR_{adj} $] 0.76; 95% CI 0.62, 0.93; p = 0.008]. Major bleeding was significantly increased with streptokinase-enoxaparin compared with FSL-UFH ($ OR_{adj} $ 2.74; 95% CI 1.81; 4.14; p<0.001) but intracranial haemorrhage (ICH) was similar ($ OR_{adj} $ 0.90; 95% CI 0.40, 2.01; p = 0.79). Net clinical outcomes, defined as either death/MI/major bleeding or as death/MI/ICH tended to favour streptokinase-enoxaparin compared with FSL-UFH ($ OR_{adj} $ 0.88; 95% CI 0.73, 1.06; p = 0.17; and $ OR_{adj} $ 0.77; 95% CI 0.63,0.93; p = 0.008, respectively). Patients receiving FSL-enoxaparin (n = 8142) and streptokinase-enoxaparin therapies experienced similar adjusted rates of the primary endpoint ($ OR_{adj} $ 1.08; 95% CI 0.87, 1.32; p = 0.49) and net clinical outcomes. Conclusions: Our results suggest that fibrinolytic therapy with the combination of streptokinase and the potent anticoagulant agent enoxaparin resulted in similar adjusted outcomes compared with more costly regimens utilizing a FSL..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
Drugs - 69(2009), 11 vom: Juli, Seite 1433-1443 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Giraldez, Roberto R. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Enoxaparin |
| doi: |
10.2165/00003495-200969110-00003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR03320411X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR03320411X | ||
| 003 | DE-627 | ||
| 005 | 20230519174757.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2009 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2165/00003495-200969110-00003 |2 doi | |
| 035 | |a (DE-627)SPR03320411X | ||
| 035 | |a (SPR)00003495-200969110-00003-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.40 |2 bkl | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Giraldez, Roberto R. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Streptokinase and Enoxaparin as an Alternative to Fibrin-Specific Lytic-Based Regimens |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background: Enoxaparin was superior to unfractionated heparin (UFH), regardless of fibrinolytic agent in ST-elevation myocardial infarction (STEMI) patients receiving fibrinolytic therapy in ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction 25) trial. Objective: This post hoc analysis compared outcomes with streptokinase plus enoxaparin to the standard regimen of fibrin-specific lytic (FSL) plus UFH and to the newer combination of FSL plus enoxaparin. Methods: In ExTRACT-TIMI 25, STEMI patients received either streptokinase or a FSL (alteplase, reteplase or tenecteplase) at the physician’s discretion and were randomized to enoxaparin or UFH, stratified by fibrinolytic type. Thirty-day outcomes were adjusted for baseline characteristics, region, in-hospital percutaneous coronary intervention (PCI) and a propensity score for the choice of lytic. Results: The primary trial endpoint of 30-day death/myocardial infarction (MI) occurred in fewer patients in the streptokinase-enoxaparin cohort (n = 2083) compared with FSL-UFH (n = 8141) [10.2% vs 12.0%, adjusted odds ratio [$ OR_{adj} $] 0.76; 95% CI 0.62, 0.93; p = 0.008]. Major bleeding was significantly increased with streptokinase-enoxaparin compared with FSL-UFH ($ OR_{adj} $ 2.74; 95% CI 1.81; 4.14; p<0.001) but intracranial haemorrhage (ICH) was similar ($ OR_{adj} $ 0.90; 95% CI 0.40, 2.01; p = 0.79). Net clinical outcomes, defined as either death/MI/major bleeding or as death/MI/ICH tended to favour streptokinase-enoxaparin compared with FSL-UFH ($ OR_{adj} $ 0.88; 95% CI 0.73, 1.06; p = 0.17; and $ OR_{adj} $ 0.77; 95% CI 0.63,0.93; p = 0.008, respectively). Patients receiving FSL-enoxaparin (n = 8142) and streptokinase-enoxaparin therapies experienced similar adjusted rates of the primary endpoint ($ OR_{adj} $ 1.08; 95% CI 0.87, 1.32; p = 0.49) and net clinical outcomes. Conclusions: Our results suggest that fibrinolytic therapy with the combination of streptokinase and the potent anticoagulant agent enoxaparin resulted in similar adjusted outcomes compared with more costly regimens utilizing a FSL. | ||
| 650 | 4 | |a Percutaneous Coronary Intervention |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Propensity Score |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Enoxaparin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Streptokinase |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Major Bleeding |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Wiviott, Stephen D. |e verfasserin |4 aut | |
| 700 | 1 | |a Nicolau, Jose C. |e verfasserin |4 aut | |
| 700 | 1 | |a Mohanavelu, Satishkumar |e verfasserin |4 aut | |
| 700 | 1 | |a Morrow, David A. |e verfasserin |4 aut | |
| 700 | 1 | |a Antman, Elliott M. |e verfasserin |4 aut | |
| 700 | 1 | |a Giugliano, Robert P. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs |d Berlin [u.a.] : Springer, 1971 |g 69(2009), 11 vom: Juli, Seite 1433-1443 |w (DE-627)SPR033129762 |w (DE-600)2021165-X |x 1179-1950 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2009 |g number:11 |g month:07 |g pages:1433-1443 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.2165/00003495-200969110-00003 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.40 |q ASE |
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 69 |j 2009 |e 11 |c 07 |h 1433-1443 | ||